Navigation Links
Trubion Pharmaceuticals Provides Announcement Dates for Third-Quarter and Nine Months Earnings Conference Call
Date:11/3/2008

SEATTLE, Nov. 3 /PRNewswire-FirstCall/ -- Trubion Pharmaceuticals Inc. (Nasdaq: TRBN) today announced that it plans to issue earnings results for the third quarter and nine months ended Sept. 30, 2008, after the close of market on Nov. 10, 2008. The company's earnings conference call will take place Nov. 10, 2008, at 2 p.m. PST (5 p.m. EST).

Both live events will be available for viewing on Trubion's website at http://investors.trubion.com/events.cfm.

Third-Quarter and Nine Months Earnings Conference Call: 2 p.m. PST/5 p.m. EST, Nov. 10, 2008

Trubion will host a conference call and webcast to discuss its third-quarter and nine months 2008 financial results. The call will be held Nov. 10 at 2 p.m. PST (5 p.m. EST). The live event will be available on Trubion's website at http://investors.trubion.com/events.cfm, or by calling (877) 440-5804 or (719) 325-4881. A replay of the discussion will be available beginning the evening of Nov. 10 on Trubion's website or by calling (888) 203-1112 or (719) 457-0820, and entering 8489656. The telephone replay will be available through Nov. 17, 2008.

About Trubion

Trubion is a biopharmaceutical company that is creating a pipeline of novel protein therapeutic product candidates to treat autoimmune and inflammatory diseases and cancer. The company's mission is to develop a variety of first-in-class and best-in-class product candidates, customized for optimal safety, efficacy, and convenience that it believes may offer improved patient experiences. Trubion's current product candidates are novel single-chain protein, or SMIP(TM), therapeutics, and are designed using its custom drug assembly technology. Trubion's product pipeline includes CD20-directed SMIP therapeutics such as TRU-015 and SBI-087 for autoimmune and inflammatory diseases, developed under the company's Wyeth collaboration. Trubion's product pipeline also includes Trubion's proprietary product candidate, TRU-016, a novel CD37-targeted therapy for the treatment of B-cell malignancies that is currently in Phase 1/2 clinical evaluation. In addition to Trubion's current clinical stage product pipeline, the company is also developing additional product candidates that build on its product development experience. More information is available in the investors section of Trubion's website: http://investors.trubion.com.

TRBN-G

Contact:

Jim DeNike

Senior Director, Corporate Communications

Trubion Pharmaceuticals Inc.

(206) 838-0500

jdenike@trubion.com

http://www.trubion.com

Waggener Edstrom Worldwide Healthcare

Colleen Beauregard

Senior Vice President

(617) 576-5790

colleenb@waggeneredstrom.com


'/>"/>
SOURCE Trubion Pharmaceuticals Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Trubion Pharmaceuticals Announces Appointment of New Chief Medical Officer
2. Trubion Pharmaceuticals Provides Announcement Dates for Second Quarter and First Six Months Earnings Conference Call
3. Trubion Pharmaceuticals Announces Dates for Fourth-Quarter and Year-End 2007 Earnings Conference Call
4. Trubion Announces Presentations at Upcoming Investor Conferences
5. MiddleBrook Pharmaceuticals Retains National Account Firm VCG & Associates
6. Pacira Pharmaceuticals Leverages TalentManager(R) from Salary.Com(TM) to Integrate Compensation and Performance Management Processes
7. Genesis Pharmaceuticals Files Counter Claims
8. Arena Pharmaceuticals Announces Third Quarter 2008 Financial Results
9. Poniard Pharmaceuticals Reports Third Quarter 2008 Financial Results and Corporate Update
10. MiddleBrook Pharmaceuticals Schedules Conference Call and Webcast for Third Quarter 2008 Financial Results
11. ISTA Pharmaceuticals Reports Third Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/11/2018)... Texas (PRWEB) , ... August 10, 2018 , ... Dr. ... recently traveled to Asunción, Paraguay for a week-long international outpost trip to deliver dental ... affiliated colleagues and support staff, Dr. Eftekhari volunteered his time to help deliver ...
(Date:8/9/2018)... ... 2018 , ... Thousands of US women with FDA-approved silicone ... from The American Society of Plastic Surgeons (ASPS), The American Society for Aesthetic ... As an MRI is recommended by FDA after the first three years then ...
(Date:8/9/2018)... , ... August 09, 2018 , ... ... and Kathy Coover and the company’s independent distributors, customers, and employees, the newly ... hours of fundraising, exceeding the $2 million goal. 100 percent of the donations ...
(Date:8/3/2018)... ... 03, 2018 , ... Firstaid4sport have been successfully selling Mueller ... Firstaid4sport business in the 1990's and his son in law, Michael Davison has ... in the UK of sports medicine products, supplying professional and amateur sports teams ...
(Date:8/2/2018)... ... August 02, 2018 , ... Allegheny Health Network ... clinicians inside and outside the network to vital patient imaging exams, saving valuable ... joins other leading hospital systems nationwide in using lifeIMAGE, which expands access to ...
Breaking Medicine News(10 mins):
(Date:8/11/2018)... ... August 11, 2018 , ... Lefty’s the Left Hand ... games and gifts. Left-Handers are possibly the world’s largest silent minority. Fully10% of ... of prejudice, countless indignities and inconveniences, left-handers quietly learn to “adapt”without whining or ...
(Date:8/9/2018)... , ... August 09, 2018 , ... Autism is a ... others. Given how widespread autism is, (approximately 1 in 68 people have the disorder), ... there are options to help teach a child with autism methods of communication and ...
(Date:8/9/2018)... ... August 09, 2018 , ... ... Charlotte-area company cbdMD named the exclusive sponsor. , “We’re honored to have been ... such public embrace for CBD on a national level,” said cbdMD’s Chief Scientific ...
Breaking Medicine Technology: